A global analysis of 2.5 million breast cancer patients
Participants in breast cancer clinical trials are getting younger and the clinical trial landscape has become more complex as more comprehensive biomarker combinations have been identified. Find out the implications for trial design and execution.
Download our report and learn about:
The impact of changing demographics
The industry's move to more tailored, effective treatments
Key biomarker trends
Opportunities for digital twins and external control arms
